Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
中文摘要
Enveda获3.11亿美元融资，估值20亿美元，旨在推进天然来源AI药物的临床试验，用于皮肤病治疗及GLP-1减重后的体重维持。
English Summary
Enveda secured $311M at a $2B valuation to advance nature-derived AI drugs into clinical trials, targeting skin conditions and weight loss maintenance after GLP-1 use.
Original Excerpt
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.